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ARTICLE INFO

ABSTRACT

Article type:

Lung cancer is the leading cause of cancer deaths worldwide, accounting for an estimated 1.8
million deaths. Lung cancer is also the most common primary cancer leading to soft tissue (ST)
metastasis. Renal disease may occur as a direct or indirect consequence of the cancer itself (e.g., postrenal obstruction, compression, or infiltration), its treatment (e.g., radiotherapy or chemotherapy),
or its related complications (e.g., opportunistic infection). Existing evidence shows that the most
frequent primary solid tumor responsible for renal metastasis is pulmonary carcinoma, followed by
gastric, breast, soft tissue, and thyroid carcinomas. Chronic kidney disease is a potential risk factor
in the survival of patients with lung cancer. In this review, we will discuss causes of kidney injury in
relation to lung cancer, potential mechanisms of kidney injury, and treatment options.
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Implication for health policy/practice/research/medical education:
The most common primary solid tumor responsible for renal metastasis is pulmonary carcinoma. In this review, we showed that chronic
kidney disease harmfully affects the survival of individuals with pulmonary malignancy.
Please cite this paper as: Patel B, Kalan ME, Khosravian M, Tolouian A, Tolouian R, Aboufazeli M, et al. Lung cancer and kidney injury: an
updated review. J Nephropathol. 2021;10(2):e12. DOI: 10.34172/jnp.2021.12.

Introduction
Onco-nephrology is concerned with the complex
problems associated with cancer and kidney disease (1).
The development of renal disease in patients with cancer
may lead to increased toxicity of chemotherapeutic agents
or decreased distribution of chemotherapeutic agents (2).
Kidney disease is usually predictive of a diagnosis of an
underlying cancer, simultaneously or through the disease
process (3). Therefore, close attention of the oncologists is
vital for a quick diagnosis and treatment of renal disease
in cancer patients. The incidence and severity of kidney
disease differ according to the type and stage of cancer,
treatment sequence, and co-morbidities (3). In patients

with active non-renal cancer, diagnostic evaluation of a
malignant renal mass could be either an asynchronous
primary renal tumor or metastatic disease (4). A study
by Humphreys et al indicated recent developments in
controlling different types of renal diseases are associated
with cancer and its treatment; with specific emphasis on
certain conditions such as uric acid nephropathy, drug
induced thrombotic microangiopathy, bisphosphonateinduced collapsing glomerulopathy, and hematopoietic
cell transplant (HCT)-associated renal failure. Although
renal disease in cancer patients is complicated; it is
helpful to clinically considering of acute kidney injury
as pre-renal, intrinsic, and post-renal causes (5). Another
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common cause of kidney damage in cancer patients is
the medications that are prescribed for their existing
cancer(s) (6). In a study of Renal Insufficiency and
Anticancer Medications (IRMA) among 445 lung cancer
patients with renal insufficiency (7), the baseline serum
was calculated using KDIGO-KDOQI (Kidney Disease
Improving Global Outcome-Kidney Disease Outcome
Quality Initiative) definition (7,8). Between the 445
IRMA lung cancer patients, 14.4% had serum creatinine
level ≥1.24 mg/dL (110 µmol/L) and 62.1% had abnormal
renal function using the formula of Cockcroft–Gault and
55.9% using aMDRD (Abbreviated Modification of Diet
in Renal Disease) formula (7).
Lung cancer is recognized as the second most common
malignancy and the leading cause of tumor-related deaths
around the globe (9). It is generally divided into two types;
small cell lung cancer (SCLC; 15% of the cases) and nonsmall cell lung cancer (NSCLC; 85% of the cases) (10).
Lung cancer is also the most common primary cancer
resulting in soft tissue (ST) metastasis. Due to the difficulty
of diagnosing NSCLC in its early stages of cancer, more
than 30% of NSCLC patients are diagnosed with distant
metastasis (11,12). Kidneys receive about 20 to 25% of
the cardiac output (about 1.0 to 1.1 L/min) making those
susceptible to hematogenous metastasis (13). The renal
metastases from NSCLC are diagnosed at autopsy, because
renal metastases are often clinically asymptomatic (14). In a
study, when the aMDRD formula was used, the incidence
of renal insufficiency varied between cancer types, ranging
from 50.8% of breast cancer patients to 56.0% of lung
cancer patients (6). Kidney metastasis can be detected
by magnetic resonance imaging (MRI), ultrasonography,
abdominal computerized tomography (CT) scans and
positron emission tomography (PET). Kidney metastasis
can be categorized as a bilateral, exophytic, small, multiple
or wedge-shaped within the renal capsule (15). The most
common primary solid tumor that is responsible for renal
metastasis is pulmonary carcinoma, followed by thyroid,
gastric, soft tissue, and breast carcinomas (16-19). Renal
metastatic tumors often occur in the cortical area near the
glomerular vasculature (20).
The spectrum of renal disease induced by lung cancer
includes acute kidney injury (AKI), chronic kidney disease
(CKD), proteinuria, nephrotic syndrome, and electrolyte
disorders. In patients with lung cancer, the most common
renal complication is AKI.
The manifestations include pre-renal injury due
to volume depletion, intra-renal by nephrotoxic
chemotherapeutic agents (such as cisplatin-based),
tumor lysis syndrome, metastatic kidney infiltrations,
or post-renal obstruction (21). Currently, AKI also is
reported among hospitalized coronavirus disease 2019
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(COVID-19) patients, a critical group to consider among
cancer patients who had been infected simultaneously
(22-24). CKD is common in patients with lung cancer,
especially in the elderly (25). In both, patients with earlystage and advanced lung cancer, CKD affects survival and
the treatment regimen (26,27). The incidence of lung
cancer induced AKI among males was almost three times
higher than females (14). Although the paraneoplastic
nephrotic syndrome is not common, it may appear in
patients with lung cancer (28). Renal paraneoplastic
syndrome symptoms may range from asymptomatic
proteinuria to severe nephrotic syndrome. In 1% to 3%
of patients with primary lung cancer, nephrotic syndrome
caused by membrane glomerulonephritis (MGN) has been
reported. There are 49 cases of tumor-related MGN in the
literature, including nine cases of SCLC (29). One study
reported a case of SCLC without metastases discovered by
a paraneoplastic nephrotic syndrome (30). The complete
remission of cancer was achieved by chemotherapy and
radiotherapy with the resolution of nephrotic syndrome,
while tumor progression occurred at the same time with
fatal renal failure (30). It was also detected in one case
of isolated unilateral renal metastases which was induced
by lung cancer (31). Jørgensen et al suggested that the
albumin-to-creatinine ratio (ACR) can predict malignancy
in certain tissues (32). ACR was assessed in 5425 patients
for 10.3 years at the time of the first diagnosis of cancer.
They found a significant association between ACR and
lung cancer (32). A study investigated patients with
newly diagnosed SCLC from 2004 to 2011 in Taiwan.
This study showed that SCLC patients with significant
proteinuria were associated with poor nutritional status
and more severe renal insufficiency (33). In a European
case-control study, results of dipstick urinalysis check were
collected from 1026 patients with primary lung cancer.
Proteinuria was significantly more common in patients
with lung cancer as compared to the control group (30.1%
versus 8.8%; P < 0.05). The incidence of proteinuria was
significantly associated with the more progressive disease
stage. Additionally, the incidence of proteinuria was
significantly higher in patients with SCLC (37.5%) than
NSCLC (28%) (34).
Materials and Methods
Articles related to this topic were searched in Embase,
Scopus, Web of Science, PubMed and the directory of
open access journals (DOAJ), using specific combination
of keywords. The keywords used are; cancer, kidney injury,
lung cancer, acute kidney injury, chronic kidney disease,
metastasis, nephrotic syndrome, immune checkpoint
inhibitors, glomerular damage, epidermal growth factor
receptor, renal metastasis and pulmonary carcinoma.

www.nephropathol.com

Lung cancers on renal function

Mechanism of association of renal disease with lung
cancer
Various tumors can cause renal disease through different
mechanisms like paraneoplastic effect, obstruction, direct
infiltration, distant metastasis from the tumor and secretory
diarrhea (caused by hormone secretion). A study by Wen
et al suggested that tumor infiltration of the kidneys in
patients with SCLC may be considered as a mechanism
of AKI (35). Numerous cases of AKI arising from solid
tumor infiltration, usually with widespread parenchymal
replacement, have been described (36). A case report by
Dobkin et al suggested that the lung metastases-induced
progressive renal failure occurs mainly by parenchymal
distortion and tubular damage by tumor cells. However,
the renal injury may be due to sloughed parenchyma or
lymphatic obstruction, vascular invasion, thrombosis, and
tumor infiltration of the renal parenchyma (37,38).
Lung cancer drugs
Cisplatin, a commonly used chemotherapeutic agent for
lung cancer, is found to be nephrotoxic (39). Almost 20%
of patients with high-dose cisplatin therapy developed
AKI (40). Pemetrexed, a folate metabolism blockade, is
currently used in combination with cisplatin for metastatic
NSCLC and malignant mesothelioma (41). A study
reported a patient with metastatic NSCLC who developed
renal failure and tubular cell apoptosis accompanied with
nephrogenic diabetes insipidus and distal renal tubular
acidosis after consecutive treatment with pemetrexed (42).
Therefore, it is necessary to adjust the dosage of anticancer
drugs, such as platinum salts, and dose according to the
level of renal function and by suitable, validated methods
to prevent drug accumulation and decrease associated
adverse events. For this purpose, several guidelines,
publications, and handbooks are available for clinicians
for dosage adjustment of anticancer drugs in patients with
renal failure (43). However, some important anticancer
drugs, such as gemcitabine, are not nephrotoxic, therefore,
it is not necessary to reduce the dosages (7).
The spectrum of cancer-associated renal diseases
has changed over the past 20 years due to the use of
newer chemotherapeutic regimens including immune
checkpoint inhibitors (ICPIs) and epidermal growth factor
receptor (5). Immune checkpoint inhibitors target the
programmed death 1 (PD-1) signaling pathway and have
recently been approved for use in progressive pretreated
NSCLC and melanoma. Evidence suggests that immune
checkpoint inhibitors are associated with increased risk
of AKI, glomerular damage, and electrolyte disturbances
(44). A study reported six cases of AKI in patients with
lung cancer treated with ICPIs, with each case showing
evidence of acute interstitial nephritis on kidney biopsy
(45,46). By analyzing randomized clinical trials (RCT)
www.nephropathol.com

data from 3695 patients, Cortazar et al reported an overall
incidence of almost 2.2% for ICPI-associated AKI (47).
In 2018, a meta-analysis of 48 RCTs including 11 845
patients treated with immune checkpoint inhibitors had
a 4.2-fold higher risk of AKI against controls taking
non-nephrotoxic agents (48). A study examined cancer
patients treated with immune checkpoint inhibitors from
2008 to 2018 who then underwent a kidney biopsy with
reported nephrotoxicity associated with ICPIs incidence
as low as 2% when nivolumab was used alone; in contrast
to 4.5% when nivolumab and ipilimumab were used as a
combination.
In other studies, immune checkpoint inhibitors
were shown to cause acute tubulointerstitial nephritis,
thrombotic microangiopathy, nephrotic syndrome (focal
segmental glomerulosclerosis, minimal-change disease
(MCD), membranous nephropathy, pauci-immune
glomerulonephritis, and immunoglobulin A (IgA)
nephropathy (49). Proposed mechanisms include direct
lymphocytic cellular infiltration of the renal interstitium,
immune complex-mediated renal injury, vasculopathy,
and release of cytokines causing podocyte foot process
effacement (49).
Anticancer therapeutics targeted against epidermal
growth factor receptor includes gefitinib and erlotinib
for lung cancer. Gefitinib was used in the treatment of
pulmonary malignancies associated with MCD in a
single case report (50). Another case report study showed
an individual with anaplastic lymphoma kinase-positive
advanced non–small cell pulmonary carcinoma who
detected complex kidney cyst during crizotinib therapy.
(51). Epidermal growth factor receptor can be bound
by ligands that regulate renal inflammation, cell growth,
and fibrosis, potentially leading to kidney damage, as
summarized by Rayego-Mateos et al (52).
Chronic kidney disease (CKD) and dialysis
It is well-known that CKD has a relative prevalence
in cancer patients, unrelated to the malignancy type
(3). The causes of CKD in cancer consist of the effects
of nephrotoxicity of some anticancer drugs and the
glomerular diseases associated with the cancer (53).
While there are a few reports (54,55) regarding patients
with CKD following treatment of pulmonary malignancy,
chronic renal failure may harmfully impact the survival
rate of patients with pulmonary malignancy. After
adjusting for numerous contradictory factors, Wei et al
revealed that CKD increases the risk of mortality and is a
potential risk factor for lung cancer patients (56).
Yamamoto et al retrospectively analyzed data of patients
who suffered surgery for NSCLC between 2007 and 2014,
of the 671 patients, 55 had CKD (57). Furthermore,
among patients who underwent pulmonary tumor
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surgery, chronic renal failure was accompanied with poor
overall survival (57). Squamous cell carcinoma was more
frequently diagnosed in patients with CKD as compared
to patients without it. The 5-year disease-free and 5-year
overall survival rates in patients with CKD were 60.0%
and 68.9%, respectively, and for patients without CKD
were 69.7% and 80.0%, respectively. While CKD patients
have restriction in their choice of systemic treatment,
surgery remains the main support for the treatment of
pulmonary tumor in this group (57). As CKD individuals
tend to have a poor respiratory function, cardiothoracic
surgeons should cautiously choose the type of resection
to attain equilibrium between the therapeutic benefit and
harm in lung cancer patients. Few studies are available on
the perioperative morbidity of lung surgery in lung cancer
patients on dialysis (58,59). For instance, a retrospective
review of seven patients on dialysis undergoing lung
surgery was performed. In these patients, there was
a high occurrence of respiratory problems as well as
hyperkalemia, hemodynamic instability, and a tendency
for postoperative bleeding (60).
Risk of lung cancer in patients with CKD or renal
cancer
Reduced kidney function may be an independent risk
factor for cancer in older men and this risk increases
when glomerular filtration rate falls to approximately 40
ml/min, as well as in patients on dialysis or transplant
recipients (61). Therefore, CKD prevention may be a new
and valuable approach for decreasing cancer risk in the
general population (61).
The detection of primary lung cancer is difficult when
kidney cancer spreads primarily to the lungs. Bowman and
colleagues identified 151 patients undergoing systemic
targeted therapy for metastatic renal cell carcinoma
(RCC) from 2006 to 2013, and reported the proportion
and incidence rate for developing NSCLC with previous
metastatic RCC (62). The incidence rate for the progress
of NSCLC in patients with metastatic RCC was 0.87 per
100 person-years (62). Lung cancer is more prevalent
after kidney transplant (63). Therefore, vigilant attention
should be paid to transplant candidates noting; age,
smoking and medical history of cancers- especially lung
cancer (64).
Treatment of renal metastasis
Renal biopsy is an essential diagnostic technique in
diagnosing kidney disease in individuals with confirmed
malignant disease (35). The techniques to treat metastatic
kidney disease are broad, especially based on the type
of metastatic renal disease. A study of two cases with
paraneoplastic nephrotic syndrome induced by advanced
SCLC concluded that if the primary tumor is unresectable,
4
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irradiation can be the first choice in the treatment of
nephrotic syndrome (28). Verma et al reported 4 cases of
solitary kidney metastasis in individuals with pulmonary
malignancy that experienced stereotactic body radiation
therapy (SBRT) and concluded that SBRT for mitigation
of renal metastases from NSCLC is a safe and effective
treatment (65). Nephrectomy may also be a beneficial
choice in the treatment of solitary kidney metastasis in
individuals with NSCLC (66). In this regard, Adamy et
al examined the effect of nephrectomy in patients with
solitary renal metastatic tumors and suggested that surgical
resection may be an appropriate approach with a positive
effect on the patients’ survival rate (67). In highly selected
cases, patients with metastatic NSCLC, have surgical
resection of extrathoracic metastasis to reduce symptoms
and increase disease-free time (68). In addition, a case
report by Degn et al examined whether the minimally
invasive procedure of cryoablation was a possible
treatment in the control of solitary kidney metastasis from
pulmonary malignancy (69). While this treatment is not
the standard of care, this case report revealed the ongoing
and new advancements in onco-nephrology and therapy
of metastatic lung cancer to the kidneys.
Conclusion
Lung cancer is recognized as the second most common
cancer and the leading cause of cancer-related deaths
worldwide. Lung cancer is also the most common primary
cancer leading to recognized soft tissue metastasis.
Kidneys receive about 25% of the cardiac output
making them susceptible to hematogenous metastasis.
The most common primary solid tumor responsible for
renal metastasis is pulmonary carcinoma. In this review,
we found that CKD harmfully affects the survival of
individuals with pulmonary malignancy and the reduced
kidney function may be a potential risk factor for cancer.
Additionally, we found that the renal disease has arisen
from lung cancer or its treatments such as immune
checkpoint inhibitors. Future observational and RCT
studies are warranted to comprehensively investigate the
impacts of lung cancer on renal function and structure to
better guide the clinicians in treating patients and saving
lives.
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